Journal
BIOCHEMICAL PHARMACOLOGY
Volume 171, Issue -, Pages -Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bcp.2019.113696
Keywords
Differentiation therapy; Retinoic acid; RAR alpha; PTMs
Categories
Funding
- National Natural Science Foundation of China [81973354, 81803552]
Ask authors/readers for more resources
Retinoic acid (RA) is a well-known differentiation inducer that exerts its effects by binding to nuclear RA receptors. Retinoic acid receptor alpha (RAR alpha), as an important nuclear RA receptor, is activated upon RA binding and facilitates the transcription of target genes related to differentiation, which ultimately initiates cell differentiation. Previous studies have found that the transcriptional activity of RAR alpha is regulated by various post-translational modifications, which influence its DNA binding efficiency, transactivation ability and even lead to degradation. Post-translational modifications of RAR alpha, as a consequence, play an important role in the RA-induced differentiation process. Therefore, in this review, we focus on recent advances in the understanding of how these modifications affect the activity of RAR alpha as well as strategies to increase the differentiation effect of RA treatment in cancer cells based on RAR alpha modifications, which may promote the development of novel effective differentiation therapies for cancer treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available